Oral Semaglutide Demonstrates Benefits for Patients With Type 2 Diabetes – Drug for nerve pain boosts high for opioid abusers.

2507_GraphicImage_062315-piAabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

Oral Semaglutide Demonstrates Benefits for Patients With Type 2 Diabetes – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889

A global phase 3a trial successfully demonstrated greater reductions in HbA1c and body weight with a oral semaglutide drug treatment than with dulaglutide, as well as a a comparable number of adverse events in 458 Japanese adults with type 2 diabetes between these medications. The 57-week randomized PIONEER 10 trial compared 3mg, 7mg, and 14 mg oral semaglutide versus 0.75 mg of once-weekly subcutaneous dulaglutide, a dosage approved by Japan’s Pharmaceutical and Medical Devices Agency.1

During the PIONEER 10 trial, which tested the safety, tolerability and efficacy of oral semaglutide, both drugs were used in combination with 1 oral antidiabetic drug, according to Novo Nordisk, whose officials announced the study results Thursday, in a prepared statement. Oral semaglutide is an investigational GLP-1 analogue taken once daily as a tablet. The FDA approved a pre-filled pen version of Novo Nordisk’s semaglutide in late 2017.2

CLICK HERE FOR CONTINUE READING

This entry was posted in Pharmacist and tagged , , , . Bookmark the permalink.

Comments are closed.